Applied Therapeutics Inc has a consensus price target of $10.04, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, UBS, and UBS on March 26, 2024, March 15, 2024, and March 6, 2024. With an average price target of $12.33 between RBC Capital, UBS, and UBS, there's an implied 79.66% upside for Applied Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/26/2024 | APLT | Buy Now | Applied Therapeutics | $6.87 | 74.8% | RBC Capital | Brian Abrahams | → $12 | Initiates | → Outperform | Get Alert |
03/15/2024 | APLT | Buy Now | Applied Therapeutics | $6.87 | 89.37% | UBS | Esther Rajavelu | $12 → $13 | Maintains | Buy | Get Alert |
03/06/2024 | APLT | Buy Now | Applied Therapeutics | $6.87 | 74.8% | UBS | Esther Rajavelu | $4 → $12 | Maintains | Buy | Get Alert |
02/22/2024 | APLT | Buy Now | Applied Therapeutics | $6.87 | 74.8% | Leerink Partners | Joseph Schwartz | → $12 | Initiates | → Outperform | Get Alert |
02/16/2024 | APLT | Buy Now | Applied Therapeutics | $6.87 | 1.97% | Citigroup | Yigal Nochomovitz | $5 → $7 | Maintains | Buy | Get Alert |
04/25/2023 | APLT | Buy Now | Applied Therapeutics | $6.87 | 103.93% | Baird | Brian Skorney | $18 → $14 | Maintains | Outperform | Get Alert |
04/05/2023 | APLT | Buy Now | Applied Therapeutics | $6.87 | -27.17% | Citigroup | Yigal Nochomovitz | $23 → $5 | Maintains | Buy | Get Alert |
08/17/2022 | APLT | Buy Now | Applied Therapeutics | $6.87 | 235.03% | Citigroup | Yigal Nochomovitz | $29 → $23 | Maintains | Buy | Get Alert |
08/16/2022 | APLT | Buy Now | Applied Therapeutics | $6.87 | -67.23% | Barclays | Carter Gould | $2.5 → $2.25 | Maintains | Equal-Weight | Get Alert |
05/20/2022 | APLT | Buy Now | Applied Therapeutics | $6.87 | 322.43% | Citigroup | Yigal Nochomovitz | $30 → $29 | Maintains | Buy | Get Alert |
03/21/2022 | APLT | Buy Now | Applied Therapeutics | $6.87 | -63.58% | Barclays | Carter Gould | $7 → $2.5 | Maintains | Equal-Weight | Get Alert |
01/04/2022 | APLT | Buy Now | Applied Therapeutics | $6.87 | 1.97% | Barclays | Carter Gould | $44 → $7 | Downgrade | Overweight → Equal-Weight | Get Alert |
08/27/2021 | APLT | Buy Now | Applied Therapeutics | $6.87 | 45.67% | Goldman Sachs | Madhu Kumar | — | Downgrade | Neutral → Sell | Get Alert |
The latest price target for Applied Therapeutics (NASDAQ: APLT) was reported by RBC Capital on March 26, 2024. The analyst firm set a price target for $12.00 expecting APLT to rise to within 12 months (a possible 74.80% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Applied Therapeutics (NASDAQ: APLT) was provided by RBC Capital, and Applied Therapeutics initiated their outperform rating.
There is no last upgrade for Applied Therapeutics.
The last downgrade for Applied Therapeutics Inc happened on January 4, 2022 when Barclays changed their price target from $44 to $7 for Applied Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Applied Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Applied Therapeutics was filed on March 26, 2024 so you should expect the next rating to be made available sometime around March 26, 2025.
While ratings are subjective and will change, the latest Applied Therapeutics (APLT) rating was a initiated with a price target of $0.00 to $12.00. The current price Applied Therapeutics (APLT) is trading at is $6.87, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.